Leadership Changes, New Studies, Acquisitions, New Care Facilities, and Business Transformations - Research Report on Cigna, HeartWare, Acadia, Magellan, and Haemonetics

Tue Jun 25, 2013 8:02am EDT

* Reuters is not responsible for the content in this press release.

Leadership Changes, New Studies, Acquisitions, New Care Facilities, and Business Transformations - Research Report on Cigna, HeartWare, Acadia, Magellan, and Haemonetics

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 25, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting CIGNA Corporation (NYSE: CI), HeartWare International Inc. (NASDAQ: HTWR), Acadia Healthcare Company Inc. (NASDAQ: ACHC), Magellan Health Services Inc. (NASDAQ: MGLN), and Haemonetics Corporation (NYSE: HAE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

CIGNA Corporation Research Report

On June 20, 2013, CIGNA Corporation (Cigna) announced the promotion of Peter McCauley, M.D., to the position of Regional Medical Executive for the Company's Northeast region, an area that includes 25 states in New England, the Northeast, the Midwest and plains states, and Maryland, Virginia, and Washington, D.C. In this position, he will oversee a team of five market medical executives and 13 clinical program consultants. Cigna's market medical executives and clinical program consultants help employer clients develop health benefit plans and they also work with physician groups and hospital systems to implement Cigna programs. The Company stated that McCauley will continue to retain his current position as market medical executive for the Midwest. The Full Research Report on CIGNA Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/700b_CI]

--

HeartWare International Inc. Research Report

On June 17, 2013, HeartWare International Inc. (HeartWare) announced that the US Food and Drug Administration (FDA) has granted conditional approval to an IDE (Investigational Device Exemption) supplement that allows the Company to commence enrollment in an additional patient cohort for ENDURANCE, the Company's pivotal clinical study to evaluate the use of HeartWare Ventricular Assist System as a Destination Therapy in advanced heart failure patients. The Company stated that in this supplemental cohort, the Company will enroll up to an additional 240 HeartWare HVAD patients, as well as up to an additional 120 control patients using a randomization scheme consistent with the ENDURANCE protocol. The patients will be studied for 12 months after the implant, and the Company intends to include the data from this new cohort into an anticipated Pre-Market Approval (PMA) Application seeking approval of the HeartWare System for the Destination Therapy indication. The Full Research Report on HeartWare International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/086c_HTWR]

--

Acadia Healthcare Company Inc. Research Report

On June 20, 2013, Acadia Healthcare Company Inc. (Acadia) announced that it has signed a definitive agreement to purchase The Refuge, a Healing Place, an 85-bed inpatient psychiatric facility near Ocala, Florida. The Company reported that the psychiatric facility produced revenues of approximately $10 million in 2012. Joey Jacobs, Chairman and Chief Executive Officer of Acadia, said, "We are pleased with our agreement to purchase this high quality specialty inpatient psychiatric facility, which is the second transaction we have announced in Florida in 2013. Consistent with our ongoing acquisition strategy, we expect this transaction to be accretive to our financial results and to represent a long-term growth opportunity for Acadia." The transaction is expected to be completed during Q3 2013, subject to customary closing conditions. The Full Research Report on Acadia Healthcare Company Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/c950_ACHC]

--

Magellan Health Services Inc. Research Report

On June 12, 2013 Magellan Health Services Inc. (Magellan) announced the launch of Magellan Complete Care in Florida, a new Medicaid HMO health plan, initially serving Broward County. According to the Company, Magellan Complete Care helps those who are most challenged to navigate the health care system, and provides the necessary support for members to improve their access to care and quality of life. Through the Company's Care Coordination Team, Magellan Complete Care reportedly manages mental and physical healthcare for all its members. Scott R. Markovich, President of Magellan Complete Care, said, "We see great opportunities to leverage Magellan's significant resources and create an entirely new integrated care offering to help states grappling with how to provide quality health care at affordable costs." The Full Research Report on Magellan Health Services Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/4d84_MGLN]

--

Haemonetics Corporation Research Report

On June 19, 2013, Haemonetics Corporation (Haemonetics) announced several developments in the pursuit of its previously announced manufacturing transformation. First, the Company stated that Haemonetics has selected Sanmina Corporation for the future production of medical devices currently manufactured in Braintree, Massachusetts. Second, a location in Penang, Malaysia, has been selected for the Company's Asian manufacturing facility. Haemonetics stated that this location offers it proximity to customers in its fastest growing markets and to a number of key suppliers and medical equipment manufacturers, including Sanmina Corporation facilities. Third, the Company announced plans to cease production operations at its manufacturing facility in Ascoli-Pisceno, Italy, during the current fiscal year 2014. Production of whole blood disposable sets, currently produced in Ascoli-Piceno, will be transferred to the Company's manufacturing facilities in Tijuana, Mexico and Covina, California. The Full Research Report on Haemonetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/7366_HAE]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


SOURCE Wall Street Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.